| Literature DB >> 29295491 |
Joanna Kocot1, Piotr Dziemidok2,3, Małgorzata Kiełczykowska4, Jacek Kurzepa5, Grzegorz Szcześniak6, Irena Musik7.
Abstract
A growing interest in the role of vitamin D in metabolic diseases led us to study the relationships between 25-hydroxyvitamin D₃ (25(OH)D₃) and the profiles of selected adipokines in type 2 diabetic (T2DM) patients. The study comprised 92 type 2 diabetics divided into quartiles regarding 25(OH)D₃ concentration. Each group was divided into male and female subgroups. All the studied patients had their anthropometric and biochemical parameters determined. Plasma 25-hydroxyvitamin D₃ concentration was determined by HPLC, while the selected adipokines (leptin, adiponectin, resistin and visfatin) by ELISA methods. The ratio of leptin to adiponectin (L/A) was calculated for all the patients. In 85.3% of diabetics a full (<20 ng/mL) or moderate (20-30 ng/mL) vitamin D deficit was found. Irrespective of sex, plasma leptin concentration decreased across increasing quartiles of 25(OH)D₃ level. In women, 25(OH)D₃ was negatively correlated with BMI, leptin level as well as L/A ratio, and positively with adiponectin concentration. In men, 25(OH)D₃ was positively correlated with HDL and negatively with systolic blood pressure (SBP), leptin level and L/A ratio. Considering all the patients, there ocurred a significant negative correlation between 25(OH)D₃ and SBP, BMI, WHR, TG, leptin and L/A ratio and positive ones between 25(OH)D₃ and both adiponectin and HDL. The results of the study support the existence of the relationship among vitamin D, obesity and leptin in type 2 diabetic patients.Entities:
Keywords: adipokines; obesity; type 2 diabetes; vitamin D
Mesh:
Substances:
Year: 2017 PMID: 29295491 PMCID: PMC5800119 DOI: 10.3390/ijerph15010019
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
The general characteristics of type 2 diabetic patients according to 25(OH)D3 status.
| 25(OH)D3 (ng/mL) | <10.87 | 10.88–19.41 | 19.42–25.81 | >25.82 | |
| Age | 59.00 | 53.50 | 30.00 | 57.00 | 55.00 |
| BMI (kg/m2) | 32.33 | 24.30 | 23.99 | 25.36 | 25.36 |
| WHR | 0.94 ± 0.09 | 0.84 ± 0.08 | 0.84 ± 0.09 | 0.89 ± 0.09 | 0.88 ± 0.09 |
| SBP (mmHg) | 134.42 ± 20.72 | 141.72 ± 22.90 | 136.23 ± 22.10 | 145.08 ± 13.66 | 139.25 ± 19.98 |
| DBP (mmHg) | 74.67 ± 11.77 | 77.73 ± 11.69 | 83.92 ± 12.51 | 78.00 ± 7.89 | 78.71 ± 11.32 |
| HbA1c (%) | 8.34 ± 2.33 | 7.09 ± 2.79 | 6.89 ± 2.00 | 8.30 ± 2.33 | 7.71 ± 2.37 |
| TC (mg/dL) | 172.63 ± 60.97 | 187.17 ± 39.83 | 178.62 ± 27.69 | 185.00 ± 28.97 | 180.98 ± 39.83 |
| TG (mg/dL) | 135.10 ± 56.08 | 111.25 ± 46.89 | 89.46 ± 38.43 | 128.91 ± 119.43 | 114.50 ± 71.129 |
| HDL (mg/dL) | 57.00 ± 17.02 | 61.17 ± 8.84 | 68.00 ± 16.13 | 69.75 ± 20.58 | 64.21 ± 16.49 |
| LDL (mg/dL) | 91.09 ± 43.09 | 105.63 ± 32.13 | 92.67 ± 27.71 | 91.63 ± 14.29 | 95.29 ± 30.28 |
| 25(OH)D3 (ng/mL) | <12.09 | 12.10–17.03 | 17.04–2.29 | >22.30 | |
| Age | 45.41 ± 15.76 | 50.63 ± 14.73 | 47.75 ± 13.61 | 43.25 ± 13.74 | 46.68 ± 14.27 |
| BMI (kg/m2) | 34.01 ± 14.03 | 33.36 ± 9.36 | 30.81 ± 6.76 | 24.49 ± 3.59 | 30.61 ± 9.73 |
| WHR | 0.99 ± 0.10 | 1.00 ± 0.11 | 0.98 ± 0.08 | 0.90 ± 0.04 | 0.97 ± 0.09 |
| SBP (mmHg) | 150.50 ± 27.54 | 145.54 ± 32.81 | 137.27 ± 25.63 | 122.58 ± 13.95 *, # (T) | 138.86 ± 27.14 |
| DBP (mmHg) | 87.91 ± 22.85 | 84.63 ± 15.56 | 87.00 ± 11.05 | 75.41 ± 10.05 | 83.65 ± 16.10 |
| HbA1c (%) | 7.79 ± 2.57 | 7.28 ± 1.62 | 7.01 ± 2.19 | 6.26 ± 1.79 | 7.07 ± 2.09 |
| TC (mg/dL) | 171.58 ± 50.41 | 181.60 ± 45.2 | 204.83 ± 45.5 | 173.08 ± 44.29 | 182.82 ± 46.97 |
| TG (mg/dL) | 171.00 | 111.00 | 144.00 | 103.00 | 112.00 |
| HDL (mg/dL) | 40.50 | 49.50 | 48.50 | 63.00 | 46.50 |
| LDL (mg/dL) | 99.80 (93.40–122.60) | 107.66 (98.00–131.20) | 129.20 (106.60–138.00) | 87.40 (54.10–111.10) | 100.80 (87.40–129.80) |
BMI: body mass index, WHR: waist-hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, HbA1c: glycated hemoglobin, TC: total cholesterol, TG: triglycerides, HDL: high-density lipoprotein, LDL: low-density lipoprotein. Normally distributed variables were expressed as mean ± SD, non-normal distributed ones as median and quartiles. * p = 0.03: Q4 vs. Q 1; # p = 0.02: Q4 vs. Q2; a p = 0.05: Q3 vs. Q1. T Tukey’s post-hoc test; K Kruskal-Wallis one way analysis of variance.
Figure 1Concentration of adipokines in type 2 diabetics divided according to plasma 25(OH)D3 level. A: leptin in T2DM women; B: leptin in T2DM men; C: adiponectin in T2DM women; D: adiponectin in T2DM men; E: resistin in T2DM women; F: resistin in T2DM men; G: visfatin in T2DM women; H: visfatin inT2DM men. * p < 0.05 vs. quartile I, ** p < 0.01 vs. quartile I, *** p < 0.001 vs. quartile I. Guartile I: the lowest 25(OH)D3 concentration, quartile IV: the highest 25(OH)D3 concentration.
Figure 2Leptin/adiponectin ratio in type 2 diabetic women (A) and men (B) divided according to plasma 25(OH)D3 level. * p < 0.05 vs. quartile I, *** p < 0.001 vs. quartile I, # p < 0.05 vs. quartile II.
Correlations between 25-hydroxyvitamin D3 and anthropometric indices, biochemical parameters as well as adipokines among type 2 diabetic patients.
| 25(OH)D3 (ng/mL) | ||||||
|---|---|---|---|---|---|---|
| Women ( | Men ( | Total ( | ||||
| Age | −0.21 | 0.19 | −0.12 | 0.47 | −0.16 | 0.17 |
| BMI (kg/m2) | −0.38 | 0.015 | −0.30 | 0.07 | −0.36 | 0.001 |
| WHR | −0.30 | 0.06 | −0.30 | 0.06 | −0.33 | 0.003 |
| SBP (mmHg) | −0.019 | 0.91 | −0.51 | 0.04 | −0.43 | 0.0003 |
| DBP (mmHg) | −0.04 | 0.83 | −0.02 | 0.94 | −0.21 | 0.09 |
| HbA1c (%) | 0.18 | 0.40 | −0.01 | 0.96 | −0.08 | 0.51 |
| TC (mg/dL) | 0.16 | 0.34 | 0.02 | 0.92 | 0.09 | 0.43 |
| TG (mg/dL) | 0.30 | 0.08 | −0.19 | 0.29 | −0.26 | 0.03 |
| HDL (mg/dL) | 0.243 | 0.16 | 0.35 | 0.03 | 0.30 | 0.01 |
| LDL (mg/dL) | 0.06 | 0.71 | 0.06 | 0.72 | 0.02 | 0.84 |
| Leptin (ng/mL) | −0.65 | 0.000007 | −0.53 | 0.0007 | −0.52 | 0.000001 |
| Adiponectin (µg/mL) | 0.33 | 0.044 | 0.23 | 0.17 | 0.26 | 0.02 |
| L/A ratio | −0.63 | 0.00005 | −0.57 | 0.0002 | −0.54 | 0.000002 |
| Resistin (µg/mL) | −0.11 | 0.49 | 0.12 | 0.47 | 0.01 | 0.92 |
| Visfatin (µg/mL) | 0.03 | 0.90 | 0.30 | 0.07 | 0.10 | 0.42 |
BMI: body mass index, WHR: waist-hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, HbA1c: glycated hemoglobin, TC: total cholesterol, TG: triglycerides, HDL: high-density lipoprotein, LDL: low-density lipoprotein. To evaluate relationships among studied parameters Spearman’s rank correlation coefficient test was applied.